Bio Farma: Indofarma Transformation Begins to Show Positive Results
PT Bio Farma (Persero) has stated that the transformation being carried out at PT Indofarma (Persero) Tbk is beginning to show positive results. The improvements have been achieved through efficiency measures, cost control, strengthened governance, and optimisation of operational processes as part of the transformation agenda within the State-Owned Pharmaceutical Holding.
Bio Farma President Director Shadiq Akasya said the transformation being implemented across all Bio Farma Group entities is not only oriented towards short-term performance improvements but also towards building a stronger and more sustainable business foundation.
According to him, Bio Farma continues to drive transformation and continuous improvement across all subsidiaries and affiliates to strengthen governance, enhance operational discipline, optimise assets and business capacity, and build healthier business competitiveness. One of the positive developments from this agenda is visible at Indofarma, which continues to carry out fundamental improvements in a disciplined and measured manner.
“Bio Farma continues to drive transformation and continuous improvement across all subsidiaries and affiliates to strengthen governance, operations, and business competitiveness. At Indofarma, the improvement measures have shown positive development through efficiency, cost control, and operational optimisation. This commitment is part of the Bio Farma Group’s efforts to support the strengthening of national health resilience and the contribution of Indonesia’s health industry at the global level,” said Shadiq.
He explained that strengthening governance and operational discipline serves as an important foundation for every entity in facing the increasingly complex challenges of the health industry. Therefore, Bio Farma will continue to oversee the transformation process through increased accountability, portfolio and asset optimisation, strengthening of production capabilities, and business development aligned with market needs and national health priorities.
Shadiq added that the Bio Farma Group will also strengthen synergy between entities to build a more integrated, resilient, and competitive health industry ecosystem. This step is expected to support the business sustainability of all group members while strengthening the contribution of the Indonesian pharmaceutical industry in safeguarding national health resilience and enhancing competitiveness at the global level.